Year |
Citation |
Score |
2022 |
Polcher A, Wolfsgruber S, Peters O, Frölich L, Wiltfang J, Kornhuber J, Hüll M, Rüther E, Lewczuk P, Maier W, Jessen F, Wagner M. A Comparison of Operational Definitions for Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 35811516 DOI: 10.3233/JAD-215548 |
0.342 |
|
2022 |
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. Jama Neurology. PMID 35099509 DOI: 10.1001/jamaneurol.2021.5216 |
0.35 |
|
2022 |
Martino Adami PV, Orellana A, García P, Kleineidam L, Alarcón-Martín E, Montrreal L, Aguilera N, Espinosa A, Abdelnour C, Rosende-Roca M, Tartari JP, Vargas L, Mauleón A, Esteban-De Antonio E, López-Cuevas R, et al. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. Brain : a Journal of Neurology. PMID 35088840 DOI: 10.1093/brain/awac024 |
0.403 |
|
2020 |
Kleineidam L, Chouraki V, Próchnicki T, van der Lee SJ, Madrid-Márquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, Martino Adami PV, Lewczuk P, Popp J, Brosseron F, Jansen IE, et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica. PMID 32166339 DOI: 10.1007/S00401-020-02138-6 |
0.486 |
|
2019 |
van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet. Neurology. PMID 31526625 DOI: 10.1016/S1474-4422(19)30283-2 |
0.467 |
|
2019 |
Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, et al. What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. European Archives of Psychiatry and Clinical Neuroscience. PMID 31463563 DOI: 10.1007/S00406-019-01055-4 |
0.306 |
|
2019 |
Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Habel U, Rüther E, Timm J, Gründer G. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 30981585 DOI: 10.1016/J.Euroneuro.2019.03.014 |
0.33 |
|
2018 |
Mattsson N, Groot C, Jansen WJ, Landau S, Villemagne V, Engelborghs S, Mintun M, Lleo A, Molinuevo JL, Jagust W, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29601787 DOI: 10.1016/J.Jalz.2018.02.009 |
0.442 |
|
2017 |
Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, et al. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. Jama Psychiatry. PMID 29188296 DOI: 10.1001/Jamapsychiatry.2017.3391 |
0.453 |
|
2017 |
Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, et al. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimer's Research & Therapy. 9: 84. PMID 29017593 DOI: 10.1186/S13195-017-0301-7 |
0.468 |
|
2017 |
Wolfsgruber S, Polcher A, Koppara A, Kleineidam L, Frölich L, Peters O, Hüll M, Rüther E, Wiltfang J, Maier W, Kornhuber J, Lewczuk P, Jessen F, Wagner M. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 28527210 DOI: 10.3233/Jad-161252 |
0.477 |
|
2017 |
Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, et al. Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How? Pharmacopsychiatry. PMID 28505669 DOI: 10.1055/S-0043-106436 |
0.316 |
|
2017 |
Polcher A, Wolfsgruber S, Frölich L, Peters O, Hüll M, Rüther E, Wiltfang J, Maier W, Kornhuber J, Lewczuk P, Jessen F, Wagner M. Application Of The ‘A/T/N’ Biomarker Classification System In Patients With Mild Cognitive Impairment: Conversion Rates To Ad And Other Dementias Alzheimers & Dementia. 13: 1310. DOI: 10.1016/J.Jalz.2017.06.2005 |
0.456 |
|
2017 |
Karaca I, Walliser C, Wagner H, Rüther E, Frölich L, Peters O, Hüll M, Popp J, Lewczuk P, Kornhuber J, Wiltfang J, Heneka M, Walter J, Jessen F, Maier W, et al. FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE Cγ2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER’S DISEASE Alzheimers & Dementia. 13: 997. DOI: 10.1016/J.Jalz.2017.06.1376 |
0.387 |
|
2016 |
Bey K, Wolfsgruber S, Karaca I, Wagner H, Lardenoije R, Becker J, Milz E, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, Wiltfang J, Riedel-Heller S, Scherer M, et al. No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics. PMID 27092400 DOI: 10.2217/epi-2015-0014 |
0.356 |
|
2016 |
Schulz C, Timm J, Cordes J, Gründer G, Mühlbauer B, Rüther E, Heinze M. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clinical Trials (London, England). 13: 251-9. PMID 27016729 DOI: 10.1177/1740774516639910 |
0.301 |
|
2016 |
Peters O, Heuser I, Frölich L, Rüther E, Rienhoff O, Kornhuber J, Wiltfang J, Maier W. [Dementia Competence Network. Results and outlook]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 59: 438-43. PMID 26979717 DOI: 10.1007/S00103-016-2314-Y |
0.436 |
|
2016 |
Louwersheimer E, Wolfsgruber S, Espinosa A, Lacour A, Heilmann-Heimbach S, Alegret M, Hernández I, Rosende-Roca M, Tárraga L, Boada M, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, et al. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26921674 DOI: 10.1016/J.Jalz.2016.01.006 |
0.481 |
|
2015 |
Peters O, Fuentes M, Joachim LK, Jessen F, Luckhaus C, Kornhuber J, Pantel J, Hüll M, Schmidtke K, Rüther E, Möller HJ, Kurz A, Wiltfang J, Maier W, Wiese B, et al. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 1: 198-204. PMID 29854939 DOI: 10.1016/J.Trci.2015.10.001 |
0.458 |
|
2015 |
Koppara A, Wolfsgruber S, Kleineidam L, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz HJ, et al. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 26484902 DOI: 10.3233/Jad-150257 |
0.479 |
|
2015 |
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 313: 1924-38. PMID 25988462 DOI: 10.1001/Jama.2015.4668 |
0.361 |
|
2015 |
Morgen K, Schneider M, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, et al. Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. Alzheimer's Research & Therapy. 7: 27. PMID 25984242 DOI: 10.1186/S13195-015-0111-8 |
0.449 |
|
2015 |
Heilmann S, Drichel D, Clarimon J, Fernández V, Lacour A, Wagner H, Thelen M, Hernández I, Fortea J, Alegret M, Blesa R, Mauleón A, Roca MR, Kornhuber J, Peters O, et al. PLD3 in non-familial Alzheimer's disease. Nature. 520: E3-5. PMID 25832411 DOI: 10.1038/Nature14039 |
0.412 |
|
2015 |
Wolfsgruber S, Jessen F, Koppara A, Kleineidam L, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, et al. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology. 84: 1261-8. PMID 25716354 DOI: 10.1212/Wnl.0000000000001399 |
0.471 |
|
2015 |
Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain : a Journal of Neurology. 138: 1327-38. PMID 25693589 DOI: 10.1093/Brain/Awv029 |
0.47 |
|
2015 |
Wolfsgruber S, Polcher AA, Koppara A, Kleineidam L, Schmidtke K, Frölich L, Hampel H, Heuser I, Peters O, Jahn H, Luckhaus C, Reischies FM, Hüll M, Gertz H, Schröder J, et al. Using neuropsychological criteria to distinguish between memory clinic patients with subjective cognitive decline and MCI Alzheimers & Dementia. 11. DOI: 10.1016/J.Jalz.2015.08.102 |
0.44 |
|
2015 |
Koppara A, Wolfsgruber S, Kleineidam L, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz H, et al. The latent dementia phenotype δ is associated with the CSF Alzheimer's disease biomarker signature in subjects with mild cognitive impairment Alzheimers & Dementia. 11: 176. DOI: 10.1016/J.Jalz.2015.07.139 |
0.474 |
|
2014 |
Thelen M, Razquin C, Hernández I, Gorostidi A, Sánchez-Valle R, Ortega-Cubero S, Wolfsgruber S, Drichel D, Fliessbach K, Duenkel T, Damian M, Heilmann S, Slotosch A, Lennarz M, Seijo-Martínez M, et al. Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging. 35: 2657.e13-9. PMID 25042114 DOI: 10.1016/J.Neurobiolaging.2014.06.018 |
0.428 |
|
2014 |
Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E, Kummer MP, Cruchaga C, Hoffmann P, Teunissen C, Holstege H, et al. SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics. 23: 6644-58. PMID 25027320 DOI: 10.1093/Hmg/Ddu372 |
0.394 |
|
2014 |
Wolfsgruber S, Wagner M, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, et al. Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. Plos One. 9: e100812. PMID 25019225 DOI: 10.1371/Journal.Pone.0100812 |
0.437 |
|
2014 |
Morgen K, Ramirez A, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, et al. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S269-76. PMID 24613704 DOI: 10.1016/J.Jalz.2013.11.001 |
0.462 |
|
2014 |
Grohmann R, Engel RR, Möller HJ, Rüther E, Van Der Velden JW, Stübner S. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: Data from the AMSP study European Archives of Psychiatry and Clinical Neuroscience. 264: 131-141. PMID 23835526 DOI: 10.1007/S00406-013-0419-Y |
0.322 |
|
2014 |
Ramirez A, Heilmann S, Drichel D, Hernandez I, Lleó A, Lacour A, Rosende-Roca M, Mauleon A, Ruiz S, Alegret M, Espinosa A, Sotolongo O, Blesa R, Fortea J, Kornhuber J, et al. Role Of Pld3 Rare Variants In European Sporadic Alzheimer'S Disease Patients Alzheimers & Dementia. 10. DOI: 10.1016/J.Jalz.2014.05.281 |
0.444 |
|
2014 |
Wolfsgruber S, Wagner M, Schmidtke K, Frolich L, Peters O, Heuser I, Jahn H, Rüther E, Wiltfang J, Maier W, Kornhuber J, Jessen F. Subjective Cognitive Decline Is Associated With Csf Amyloid B 1-42, Depressive Symptoms And Episodic Memory Performance In Patients With Mild Cognitive Impairment Alzheimers & Dementia. 10: 312. DOI: 10.1016/J.Jalz.2014.05.257 |
0.449 |
|
2013 |
Morgen K, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Hampel H, et al. APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 37: 389-401. PMID 23948881 DOI: 10.3233/Jad-130326 |
0.48 |
|
2013 |
Wolfsgruber S, Wagner M, Wiltfang J, Maier W, Frolich L, Peters O, Rüther E, Klaus S, Heuser I, Kornhuber J, Jessen F. P4-154: Subjective memory concerns, objective memory impairment and risk of Alzheimer's dementia in people with MCI Alzheimer's & Dementia. 9: P761-P762. DOI: 10.1016/J.Jalz.2013.05.1545 |
0.419 |
|
2012 |
Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Rüther E, Wiltfang J. Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 805-13. PMID 22527776 DOI: 10.1007/S00702-012-0801-3 |
0.319 |
|
2012 |
Riedel M, Leucht S, Rüther E, Schmauß M, Möller HJ. Critical trial-related criteria in acute schizophrenia studies. European Archives of Psychiatry and Clinical Neuroscience. 262: 151-5. PMID 21789700 DOI: 10.1007/S00406-011-0225-3 |
0.305 |
|
2012 |
Peters O, Joachim LK, Schmidtke K, Hüll M, Rüther E, Teipel S, Möller H, Jessen F, Luckhaus C, Maier W, Wiltfang J, Kornhuber J, Frolich L, Heuser I. CSF biomarkers and disease progression in an interrupted MCI trial Alzheimers & Dementia. 8: 268. DOI: 10.1016/J.Jalz.2012.05.716 |
0.426 |
|
2012 |
Ramirez A, Herold C, Lewczuk P, Lacour A, Drichel D, Schürmann B, Kornhuber J, Peters O, Heun R, Hampel H, Frölich L, Hüll M, Hoffmann P, Vogt S, Kölsch H, et al. Genome-wide association study using cerebrospinal fluid biomarkers beta-amyloid-42 and pTau181 in German samples of Alzheimer's disease Alzheimers & Dementia. 8: 663. DOI: 10.1016/J.Jalz.2012.05.1786 |
0.42 |
|
2011 |
Schipke CG, Jessen F, Teipel S, Luckhaus C, Wiltfang J, Esselmann H, Frölich L, Maier W, Rüther E, Heppner FL, Prokop S, Heuser I, Peters O. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. Journal of Alzheimer's Disease : Jad. 26: 255-62. PMID 21606567 DOI: 10.3233/Jad-2011-110329 |
0.308 |
|
2011 |
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics. 43: 429-35. PMID 21460840 DOI: 10.1038/Ng.803 |
0.394 |
|
2009 |
Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Rüther E, Cordes J. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. The Journal of Clinical Psychiatry. 70: 1258-65. PMID 19538904 DOI: 10.4088/Jcp.08M04563 |
0.304 |
|
2009 |
Peters O, Maier W, Luckhaus C, Kornhuber J, Pantel J, Hüll M, Rüther E, Möller H, Kurz A, Wellek S, Wiltfang J, Rienhoff O, Wiese B, Frölich L, Heuser I. O1-04-08: Safety and efficacy of a galantamine/memantine combination in mild to moderate Alzheimer's disease - randomized controlled trial Alzheimer's & Dementia. 5: P86-P87. DOI: 10.1016/J.Jalz.2009.05.221 |
0.414 |
|
2006 |
Beard SM, Maciver F, Clouth J, Rüther E. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 7: 165-72. PMID 16896764 DOI: 10.1007/S10198-006-0347-0 |
0.311 |
|
2006 |
Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain : a Journal of Neurology. 129: 1177-87. PMID 16600985 DOI: 10.1093/Brain/Awl063 |
0.438 |
|
2006 |
Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki H, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J. P2-157: Expression of CSF amyloid beta peptide patterns Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.995 |
0.43 |
|
2005 |
Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Rüther E. Risperidone: An open-label observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia Journal of Clinical Psychopharmacology. 25: 293-300. PMID 16012270 DOI: 10.1097/01.Jcp.0000170686.27476.Ab |
0.316 |
|
2005 |
Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, Bleich S, Rüther E, Kornhuber J. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Research. 1052: 156-62. PMID 16009352 DOI: 10.1016/J.Brainres.2005.06.017 |
0.349 |
|
2005 |
Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Rüther E, Emrich HM, Schneider U, Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. The Journal of Neuropsychiatry and Clinical Neurosciences. 17: 227-31. PMID 15939978 DOI: 10.1176/Jnp.17.2.227 |
0.424 |
|
2004 |
Bandelow B, Rüther E. Treatment-resistant panic disorder. Cns Spectrums. 9: 725-39. PMID 15448584 DOI: 10.1017/S1092852900022379 |
0.314 |
|
2004 |
Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis. 25: 2912-8. PMID 15349929 DOI: 10.1002/Elps.200305992 |
0.414 |
|
2003 |
Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Communications in Mass Spectrometry : Rcm. 17: 1291-6. PMID 12811752 DOI: 10.1002/Rcm.1048 |
0.405 |
|
2001 |
Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. The Journal of Clinical Psychiatry. 62: 453-463. PMID 11465523 DOI: 10.4088/Jcp.V62N0609 |
0.301 |
|
2000 |
Bleich S, Degner D, Kropp S, Rüther E, Kornhuber J. Red wine, spirits, beer and serum homocysteine. The Lancet. 356: 512. PMID 10981920 DOI: 10.1016/S0140-6736(05)74186-6 |
0.347 |
|
2000 |
Wolstein J, Grohmann R, Rüther E, Hippius H. Antipsychotic drugs and venous thromboembolism. The Lancet. 356: 252. PMID 10963225 DOI: 10.1016/S0140-6736(05)74503-7 |
0.711 |
|
2000 |
Stubner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Moller H, Ruther E. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. The Journal of Clinical Psychiatry. 61: 569-574. DOI: 10.4088/Jcp.V61N0805 |
0.301 |
|
1995 |
Bandelow B, Sievert K, Röthemeyer M, Hajak G, Rüther E. What treatments do patients with panic disorder and agoraphobia get European Archives of Psychiatry and Clinical Neuroscience. 245: 165-171. PMID 7669824 DOI: 10.1007/Bf02193090 |
0.322 |
|
1995 |
Stoppe G, Schütze R, Kögler A, Staedt J, Munz DL, Emrich D, Rüther E. Cerebrovascular reactivity to acetazolamide in (senile) dementia of Alzheimer's type: relationship to disease severity. Dementia (Basel, Switzerland). 6: 73-82. PMID 7606283 DOI: 10.1159/000106925 |
0.315 |
|
1994 |
Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry. 27: 32-40. PMID 8159781 DOI: 10.1055/S-2007-1014271 |
0.366 |
|
1989 |
Schmauss M, Wolff R, Erfurth A, Rüther E. Tolerability of long term clozapine treatment. Psychopharmacology. 99: S105-8. PMID 2813663 DOI: 10.1007/Bf00442572 |
0.303 |
|
1989 |
Grohmann R, Rüther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology. 99. PMID 2813662 DOI: 10.1007/Bf00442571 |
0.306 |
|
1979 |
Beckmann B, Hippius H, Rüther E. Treatment of schizophrenia. Progress in Neuro-Psychopharmacology. 3: 47-52. PMID 45564 DOI: 10.1016/0364-7722(79)90068-7 |
0.3 |
|
Show low-probability matches. |